Details business of pathways, including, but not limited to financing and payment incentives, HEOR, predictable cost of care (PCOC), and cost modeling.
Gordon Kuntz provides a recap of the 9th annual Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), highlighting important themes and notable sessions.
Gordon Kuntz provides a recap of the 9th annual Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), highlighting important themes and notable sessions.
In this column, F. Randy Vogenberg, PhD, FASHP, reviews health care stakeholders’ final priorities for 2025 and the transition to a more complex business-driven shift in risk mitigation for 2026 health care coverage.
In this column, F. Randy Vogenberg, PhD, FASHP, reviews health care stakeholders’ final priorities for 2025 and the transition to a more complex business-driven shift in risk mitigation for 2026 health care coverage.
As unprecedented medical and technological advances outpace existing care and reimbursement models, employers and manufacturers must collaborate through data-driven, trust-based frameworks to ensure equitable access to care.
As unprecedented medical and technological advances outpace existing care and reimbursement models, employers and manufacturers must collaborate through data-driven, trust-based frameworks to ensure equitable access to care.
Congress’s effort to lower drug prices through the Inflation Reduction Act may have unintended—and potentially devastating—consequences for community oncology practices, threatening access and affordability for the majority of Americans...
Congress’s effort to lower drug prices through the Inflation Reduction Act may have unintended—and potentially devastating—consequences for community oncology practices, threatening access and affordability for the majority of Americans...
As government reforms and market pressures reshape the health insurance landscape, this column explores how employers, manufacturers, and policymakers must realign their strategies to bridge transparency gaps, manage rising costs, and sustain...
As government reforms and market pressures reshape the health insurance landscape, this column explores how employers, manufacturers, and policymakers must realign their strategies to bridge transparency gaps, manage rising costs, and sustain...
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
An environmental scan revealed that integrating psychosocial care into oncology programs—especially in underserved and rural communities—is hindered by systemic and structural barriers, prompting the development of a strategic four-part...
An environmental scan revealed that integrating psychosocial care into oncology programs—especially in underserved and rural communities—is hindered by systemic and structural barriers, prompting the development of a strategic four-part...
Kathryn Christensen, MD, MS; Timothy Dollear, MD, MS; Rama Al Ghannam, PharmD; Eric Gratias, MD, FAAP; Robinson Ortiz, MD; Stephen Hamilton, MD
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
Kathryn Christensen, MS, and colleagues share the initial results of the launch of Cigna and eviCore Healthcare’s Oncology Value-based Pathways program.
John P. Geisler, MD, PharmD, MS; Nagadharshan Devendra, MD; Kelly J. Manahan, MD, MBA
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
This study evaluates how indication-specific pricing for bevacizumab in cervical and colon cancer could align with a $100 000 per quality adjusted life-year willingness-to-pay threshold.
In this column, the Community Oncology Alliance lays out a reform plan to rescue cancer care from a profit-driven system that is failing patients and threatening the future of independent oncology practices.
In this column, the Community Oncology Alliance lays out a reform plan to rescue cancer care from a profit-driven system that is failing patients and threatening the future of independent oncology practices.